DK3151831T3 - Priming af kræftceller med lav dosis af naltrexon - Google Patents
Priming af kræftceller med lav dosis af naltrexon Download PDFInfo
- Publication number
- DK3151831T3 DK3151831T3 DK15730526.9T DK15730526T DK3151831T3 DK 3151831 T3 DK3151831 T3 DK 3151831T3 DK 15730526 T DK15730526 T DK 15730526T DK 3151831 T3 DK3151831 T3 DK 3151831T3
- Authority
- DK
- Denmark
- Prior art keywords
- naltrexon
- priming
- low dosage
- cancel cells
- cancel
- Prior art date
Links
- 230000037452 priming Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1410216.4A GB201410216D0 (en) | 2014-06-09 | 2014-06-09 | Therapeutic |
| PCT/GB2015/051686 WO2015189597A1 (en) | 2014-06-09 | 2015-06-09 | Priming of cancer cells with low dose naltrexone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3151831T3 true DK3151831T3 (da) | 2019-06-24 |
Family
ID=51266919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15730526.9T DK3151831T3 (da) | 2014-06-09 | 2015-06-09 | Priming af kræftceller med lav dosis af naltrexon |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11065245B2 (enExample) |
| EP (1) | EP3151831B1 (enExample) |
| JP (1) | JP6620338B2 (enExample) |
| DK (1) | DK3151831T3 (enExample) |
| ES (1) | ES2730348T3 (enExample) |
| GB (1) | GB201410216D0 (enExample) |
| PL (1) | PL3151831T3 (enExample) |
| PT (1) | PT3151831T (enExample) |
| TR (1) | TR201908660T4 (enExample) |
| WO (1) | WO2015189597A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201308440D0 (en) * | 2013-05-10 | 2013-06-19 | Dalgleish Angus | Therapeutic |
| EP3416619A2 (en) * | 2016-02-18 | 2018-12-26 | Immune Therapeutics, Inc. | Method for inducing a sustained immune response |
| GB201704913D0 (en) * | 2017-03-28 | 2017-05-10 | Ldn Pharma Ltd | Method |
| GB201704911D0 (en) * | 2017-03-28 | 2017-05-10 | Ldn Pharma Ltd | High dose combo I |
| GB201704909D0 (en) | 2017-03-28 | 2017-05-10 | Ldn Pharma Ltd | Cancer therapy |
| EP3482751A1 (en) | 2017-11-14 | 2019-05-15 | LDN Pharma Limited | Cancer treatment |
| EP3934647A1 (en) * | 2019-03-06 | 2022-01-12 | LDN Pharma Limited | Method for determining efficacy |
| GB201903546D0 (en) * | 2019-03-15 | 2019-05-01 | Ldn Pharma Ltd | Cancer treatment |
| CN114364402A (zh) | 2019-07-15 | 2022-04-15 | 罗瓦萨公司 | 用于治疗癌症的阿片类生长因子受体(ogfr)拮抗剂，特别是纳洛酮和/或纳曲酮 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030144312A1 (en) * | 2001-10-30 | 2003-07-31 | Schoenhard Grant L. | Inhibitors of ABC drug transporters in multidrug resistant cancer cells |
| AU2009225434B2 (en) | 2008-03-21 | 2014-05-22 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
| JP2015107918A (ja) | 2012-02-14 | 2015-06-11 | 国立研究開発法人国立がん研究センター | 抗がん剤の作用を増強する医薬組成物、がん治療用キット、診断薬、及びスクリーニング方法 |
| GB201308440D0 (en) * | 2013-05-10 | 2013-06-19 | Dalgleish Angus | Therapeutic |
-
2014
- 2014-06-09 GB GBGB1410216.4A patent/GB201410216D0/en not_active Ceased
-
2015
- 2015-06-09 PT PT15730526T patent/PT3151831T/pt unknown
- 2015-06-09 EP EP15730526.9A patent/EP3151831B1/en active Active
- 2015-06-09 TR TR2019/08660T patent/TR201908660T4/en unknown
- 2015-06-09 US US15/317,082 patent/US11065245B2/en active Active
- 2015-06-09 PL PL15730526T patent/PL3151831T3/pl unknown
- 2015-06-09 JP JP2016572543A patent/JP6620338B2/ja active Active
- 2015-06-09 DK DK15730526.9T patent/DK3151831T3/da active
- 2015-06-09 ES ES15730526T patent/ES2730348T3/es active Active
- 2015-06-09 WO PCT/GB2015/051686 patent/WO2015189597A1/en not_active Ceased
-
2021
- 2021-06-18 US US17/351,792 patent/US12144807B2/en active Active
-
2024
- 2024-10-15 US US18/916,423 patent/US20250032481A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017519006A (ja) | 2017-07-13 |
| GB201410216D0 (en) | 2014-07-23 |
| EP3151831B1 (en) | 2019-03-13 |
| US20250032481A1 (en) | 2025-01-30 |
| US11065245B2 (en) | 2021-07-20 |
| JP6620338B2 (ja) | 2019-12-18 |
| ES2730348T3 (es) | 2019-11-11 |
| PT3151831T (pt) | 2019-06-18 |
| PL3151831T3 (pl) | 2021-05-31 |
| US20210308125A1 (en) | 2021-10-07 |
| EP3151831A1 (en) | 2017-04-12 |
| WO2015189597A1 (en) | 2015-12-17 |
| US12144807B2 (en) | 2024-11-19 |
| TR201908660T4 (en) | 2019-07-22 |
| US20170119755A1 (en) | 2017-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280905A (en) | Methods of modulating drug plasma levels using erythrohydroxybupropion | |
| DK3302565T3 (da) | Faste doseringsformer af palbociclib | |
| DK3119397T3 (da) | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser | |
| DK3244948T3 (da) | Bestemmelse af medikamentdosis | |
| DK3851537T3 (da) | Behandling af hyperbilirubinæmi | |
| DK3356358T3 (da) | Mikrobiocide oxadiazolderivater | |
| DK3148625T3 (da) | Opklappelig kateterpakning | |
| DK3521282T3 (da) | Quinazolinderivater anvendt til behandling af hiv | |
| HUE037587T2 (hu) | Önálló fecskendõcsatlakozás | |
| DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
| DK3151831T3 (da) | Priming af kræftceller med lav dosis af naltrexon | |
| DK3125875T3 (da) | Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande | |
| DK3157508T3 (da) | Fast oral doseringsform af lipofile forbindelser | |
| DK3185853T3 (da) | Inhalerbare pulverformuleringer af alginatoligomerer | |
| DK3116491T3 (da) | Farmaceutiske sammensætninger af terapeutisk aktive forbindelser | |
| DK3107366T3 (da) | Priming af frø | |
| DK3099298T3 (da) | Kombinationsterapier med zidovudin til behandling af mikrobielle infektioner | |
| DK3294283T3 (da) | Sacubitril-valsartan-doseringsregime til behandling af hjerteinsufficiens | |
| DK3297653T3 (da) | Behandling af postbariatrisk hypoglykæmi med glp-1-antagonister | |
| DK3204038T3 (da) | Sammensætninger omfattende amylase til anvendelse i behandlingen af pruritus | |
| DK3094322T3 (da) | Administration af tasimelteon i fastende tilstand | |
| DK3164123T3 (da) | Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier | |
| DK3363428T3 (da) | Perfusionsdoseringsform | |
| HRP20181572T1 (hr) | Režim doziranja spoja fgf-18 | |
| DK4008329T3 (da) | Isoxazolinforbindelser til anvendelse i behandling af demodicose |